Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gopalan Raghunathan is active.

Publication


Featured researches published by Gopalan Raghunathan.


Journal of Molecular Recognition | 2012

Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens.

Gopalan Raghunathan; Jason Smart; Joseph Williams; Juan Carlos Almagro

The number of antibody structures co‐crystallized with their respective antigens has increased rapidly in the last few years, thus offering a formidable source of information to gain insight into the structure–function relationships of this family of proteins. We have analyzed here 140 unique middle‐resolution to high‐resolution (<3 Å) antibody structures, including 55 in complex with proteins, 39 with peptides, and 46 with haptens. We determined (i) length variations of the hypervariable loops, (ii) number of contacts with antigen, (iii) solvent accessible area buried upon binding, (iv) location and frequency of antigen contacting residues, (v) type of residues interacting with antigens, and (vi) putative somatic mutations. Except for somatic mutations, distinctive profiles were identified for all the variables analyzed. Compared with contacts, somatic mutations occurred with less abundance at any given position and extended beyond the regions in contact, with no clear difference among antibodies that recognize different types of antigens. This observation is consistent with the fact that although antigen recognition accomplished by shape and physicochemical complementarity is selective in nature, the somatic mutation process is stochastic and selection for mutations leading to improved affinity is not directly related to contact residues. Thus, the knowledge emerging from this study enhances our understanding of the structure–function relationship in antibodies while providing valuable guidance to design libraries for antibody discovery and optimization. Copyright


Journal of Molecular Biology | 2010

Human framework adaptation of a mouse anti-human IL-13 antibody.

Johan Fransson; Alexey Teplyakov; Gopalan Raghunathan; Ellen Chi; Wendy Cordier; Thai Dinh; Yiqing Feng; Jill Giles-Komar; Gary L. Gilliland; Bridget Lollo; Thomas J. Malia; Walter Nishioka; Galina Obmolova; Shanrong Zhao; Yonghong Zhao; Ronald V. Swanson; Juan Carlos Almagro

Humanization of a potent neutralizing mouse anti-human IL-13 antibody (m836) using a method called human framework adaptation (HFA) is reported. HFA consists of two steps: human framework selection (HFS) and specificity-determining residue optimization (SDRO). The HFS step involved generation of a library of m836 antigen binding sites combined with diverse human germline framework regions (FRs), which were selected based on structural and sequence similarities between mouse variable domains and a repertoire of human antibody germline genes. SDRO consisted of diversifying specificity-determining residues and selecting variants with improved affinity using phage display. HFS of m836 resulted in a 5-fold loss of affinity, whereas SDRO increased the affinity up to 100-fold compared to the HFS antibody. Crystal structures of Fabs in complex with IL-13 were obtained for m836, the HFS variant chosen for SDRO, and one of the highest-affinity SDRO variants. Analysis of the structures revealed that major conformational changes in FR-H1 and FR-H3 occurred after FR replacement, but none of them had an evident direct impact on residues in contact with IL-13. Instead, subtle changes affected the V(L)/V(H) (variable-light domain/variable-heavy domain) interface and were likely responsible for the 5-fold decreased affinity. After SDRO, increased affinity resulted mainly from rearrangements in hydrogen-bonding pattern at the antibody/antigen interface. Comparison with m836 putative germline genes suggested interesting analogies between natural affinity maturation and the engineering process that led to the potent HFA anti-human IL-13 antibody.


Journal of Molecular Recognition | 2012

Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.

Juan Carlos Almagro; Gopalan Raghunathan; Eric J. Beil; Dariusz J. Janecki; Qiang Chen; Thai Dinh; Ann LaCombe; Judy Connor; Mark Ware; Paul Kim; Ronald V. Swanson; Johan Fransson

Disulfide bridges are common in the antigen‐binding site from sharks (new antigen receptor) and camels (single variable heavy‐chain domain, VHH), in which they confer both structural diversity and domain stability. In human antibodies, cysteine residues in the third complementarity‐determining region of the heavy chain (CDR‐H3) are rare but naturally encoded in the IGHD germline genes. Here, by panning a phage display library designed based on human germline genes and synthetic CDR‐H3 regions against a human cytokine, we identified an antibody (M3) containing two cysteine residues in the CDR‐H3. It binds the cytokine with high affinity (0.4 nm), recognizes a unique epitope on the antigen, and has a distinct neutralization profile as compared with all other antibodies selected from the library. The two cysteine residues form a disulfide bridge as determined by mass spectrometric peptide mapping. Replacing the cysteines with alanines did not change the solubility and stability of the monoclonal antibody, but binding to the antigen was significantly impaired. Three‐dimensional modeling and dynamic simulations were employed to explore how the disulfide bridge influences the conformation of CDR‐H3 and binding to the antigen. On the basis of these results, we envision that designing human combinatorial antibody libraries to contain intra‐CDR or inter‐CDR disulfide bridges could lead to identification of human antibodies with unique binding profiles. Copyright


mAbs | 2018

Structural insights into humanization of anti-tissue factor antibody 10H10

Alexey Teplyakov; Galina Obmolova; Thomas J. Malia; Gopalan Raghunathan; Christian Martinez; Johan Fransson; Wilson Edwards; Judith Connor; Matthew Husovsky; Heena Beck; Ellen Chi; Sandra Fenton; Hong Zhou; Juan Carlos Almagro; Gary L. Gilliland

ABSTRACT Murine antibody 10H10 raised against human tissue factor is unique in that it blocks the signaling pathway, and thus inhibits angiogenesis and tumor growth without interfering with coagulation. As a potential therapeutic, the antibody was humanized in a two-step procedure. Antigen-binding loops were grafted onto selected human frameworks and the resulting chimeric antibody was subjected to affinity maturation by using phage display libraries. The results of humanization were analyzed from the structural perspective through comparison of the structure of a humanized variant with the parental mouse antibody. This analysis revealed several hot spots in the framework region that appear to affect antigen binding, and therefore should be considered in human germline selection. In addition, some positions in the Vernier zone, e.g., residue 71 in the heavy chain, that are traditionally thought to be crucial appear to tolerate amino acid substitutions without any effect on binding. Several humanized variants were produced using both short and long forms of complementarity-determining region (CDR) H2 following the difference in the Kabat and Martin definitions. Comparison of such pairs indicated consistently higher thermostability of the variants with short CDR H2. Analysis of the binding data in relation to the structures singled out the ImMunoGeneTics information system® germline IGHV1-2*01 as dubious owing to two potentially destabilizing mutations as compared to the other alleles of the same germline and to other human germlines.


Archive | 2005

Toll like receptor 3 antagonists, methods and uses

Jill Carton; Shizhong Chen; Mark Cunningham; Anuk Das; Karen E. Duffy; Jill Giles-Komar; Theresa J. Goletz; David M. Knight; Roberta Lamb; Mouhamadou L. Mbow; Kristen Picha; Gopalan Raghunathan; Lani San Mateo; Robert T. Sarisky; Vedrana Stojanovic-Susulic; Nicole Stowell; Raymond Sweet; Shanrong Zhao


Archive | 2005

Anti-respiratory syncytial virus antibodies, antigens and uses thereof

Alfred Delvecchio; Ping Tsui; Patrick Branigan; Leslee Conrad; Nicole D. Day; Changbao Liu; Raymond Sweet; Sheng-Jiun Wu; Jose Centro Nacional De Microbiologia Melero; Jinquan Luo; Gabriela Canziani; Mark Tornetta; Gopalan Raghunathan; Venkata Chalapathi Koka


Archive | 2007

Methods for use in human-adapting monoclonal antibodies

Gopalan Raghunathan


Archive | 2010

Methods of affinity maturing antibodies

Juan Carlos Almagro; Johan Fransson; Gopalan Raghunathan


Archive | 2009

Engineered anti-il-13 antibodies, compositions, methods and uses

Ronald V. Swanson; Ellen Chi; Gopalan Raghunathan; Shanrong Zhao; Johan Fransson; Wendy Cordier; Hong Mimi Zhou; Juan Carlos Almagro; Linus Hyun; Jill Giles-Komar; Karyn O'neil; Jill Carton; Alexey Teplyakov; Yiging Feng


Archive | 2008

HUMAN ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES

Marc Mercken; Jacqueline Benson; Sun-Yung S. Jung; Haiyan Jiang; Gopalan Raghunathan; Lionella Borozdina-Birch

Collaboration


Dive into the Gopalan Raghunathan's collaboration.

Top Co-Authors

Avatar

Ellen Chi

Janssen Pharmaceutica

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge